Triple
T9807338
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | faricimab |
E238184
|
entity |
| Predicate | comparedWith |
P278
|
FINISHED |
| Object | aflibercept |
E238303
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: aflibercept | Statement: [faricimab, comparedWith, aflibercept]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: aflibercept Context triple: [faricimab, comparedWith, aflibercept]
-
A.
aflibercept
chosen
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
B.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
C.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
D.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
E.
faricimab
Faricimab is a bispecific monoclonal antibody used to treat neovascular eye diseases such as wet age-related macular degeneration and diabetic macular edema by targeting both VEGF-A and Ang-2 pathways.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca84defac48190abc1148804f184c1 |
completed | March 30, 2026, 2:12 p.m. |
| NER | Named-entity recognition | batch_69cdab7ddaac8190a5584a5c863fbaa3 |
completed | April 1, 2026, 11:34 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d1cc57119881909616d835def02fc9 |
completed | April 5, 2026, 2:43 a.m. |
Created at: March 30, 2026, 8:29 p.m.